Related Experiment Video
Updated: Feb 20, 2026
Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue
Published on: January 3, 2013
BTG1 low expression in pancreatic ductal adenocarcinoma is associated with a poorer prognosis
Yufang Huang1, Jiawei Zheng1,2, Ting Tan3
11 Department of Medical Oncology, Fuzhou General Hospital of Nanjing Military Command, Fuzong Clinical College of Fujian Medical University, Fujian - PR China.
Objective:
BTG1 is a member of the TOB/BTG protein family, which is a transducer of ErbB-2 and TOB2. It is known to inhibit tumor genesis, but its role in pancreatic ductal adenocarcinoma (PDAC) is still unknown. The purpose of this study is to investigate the expression of BTG1 protein in PDAC and to determine its prognostic significance.
Methods:
Immunohistochemistry is used to determine the protein expression of the BTG1 gene in 79 surgically resected PDAC. The association of BTG1 expression with all the patients' clinicopathologic parameters, including survival, was analyzed using statistical software.
Results:
High BTG1 expression was observed in 27.8% (22/79) of the PDAC tissues, which was significantly lower than the 58.2% (46/79) of corresponding normal adjacent noncancerous tissues by immunohistochemical staining (p<0.001).Through the stratified analysis, we found a significant difference of BTG1 expression in peri-neural invasion (p = 0.002), T stage (p = 0.000), N stage (p = 0.018), and tumor, node, and metastasis stage (p = 0.000). Univariate and multivariate Cox analysis revealed that BTG1 expression status was an independent prognostic factor in PDAC (p = 0.027). Moreover, overall survival was better in PDAC cases with higher rather than lower BTG1 expression (p = 0.027).
Conclusions:
This study demonstrated for the first time that lower expression of BTG1 might be involved in the progression of PDAC, suggesting that BTG1 might be a novel prognostic marker and a target for therapy.
Insights
Lower expression of BTG1 protein is linked to pancreatic ductal adenocarcinoma (PDAC) progression. This suggests BTG1 may serve as a novel prognostic marker for PDAC patients, potentially guiding new therapeutic strategies.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- BTG1 is a member of the TOB/BTG protein family involved in ErbB-2 signaling.
- BTG1 is known to inhibit tumor genesis.
- The role of BTG1 in pancreatic ductal adenocarcinoma (PDAC) remains uncharacterized.
Purpose of the Study:
- To investigate BTG1 protein expression in PDAC tissues.
- To determine the prognostic significance of BTG1 in PDAC.
Main Methods:
- Immunohistochemistry was employed to assess BTG1 protein expression in 79 surgically resected PDAC samples.
- Statistical analysis was used to correlate BTG1 expression with clinicopathologic parameters and patient survival.
Main Results:
- BTG1 expression was significantly lower in PDAC tissues (27.8%) compared to adjacent normal tissues (58.2%).
- Reduced BTG1 expression correlated with peri-neural invasion, advanced T stage, N stage, and overall tumor stage.
- BTG1 expression was identified as an independent prognostic factor, with higher expression associated with better overall survival in PDAC patients.
Conclusions:
- Lower BTG1 expression is implicated in PDAC progression.
- BTG1 represents a potential novel prognostic marker for PDAC.
- BTG1 may serve as a therapeutic target for pancreatic cancer treatment.
